Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Day One Biopharmaceuticals Inc DAWN

Healthcare Biotechnology
Day One Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for people of all ages with life-threatening diseases. The Company partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. Its product candidates include tovorafenib, pimasertib and the VRK1 program.... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:DAWN)

Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress

GlobeNewswire February 26, 2024

Day One Announces Two New Appointments to Board of Directors

GlobeNewswire January 17, 2024

Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire December 19, 2023

Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine

GlobeNewswire November 17, 2023

Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference

GlobeNewswire November 14, 2023

Day One Reports Third Quarter 2023 Financial Results and Corporate Progress

GlobeNewswire November 6, 2023

Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

GlobeNewswire October 30, 2023

Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

GlobeNewswire September 11, 2023

Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience

GlobeNewswire August 16, 2023
View More News ››

Opinion & Analysis (NDAQ:DAWN)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:DAWN)

Be the first to post on this bullboard.

BioVaxys Technology Corp.

BioVaxys Technology Corp.

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving ...
View More »